About genmab a/s - GMAB
Genmab A/S is an international biotechnology company, which engages in the development of human antibody therapeutics for the treatment of cancer and other diseases. Its product pipeline includes daratumumab, marketed as DARZALEX for the treatment of certain indications of multiple myeloma; teprotumumab-trbw marketed as TEPEZZA for the treatment of thyroid eye disease; and ofatumumab, marketed as Arzerra for the treatment of certain indications of chronic lymphocytic leukemia. The company was founded by Donald Lee Drakeman, Florian Schonharting, and Jan G. J. van de Winkel on June 11, 1998, and is headquartered in Copenhagen, Denmark.
GMAB At a Glance
Genmab A/S
Carl Jacobsens Vej 30
Copenhagen, Central Denmark 2500
| Phone | 45-70-20-27-28 | Revenue | 2.39B | |
| Industry | Pharmaceuticals: Major | Net Income | 631.46M | |
| Sector | Health Technology | 2023 Sales Growth | 15.931% | |
| Fiscal Year-end | 12 / 2024 | Employees | 2,204 | |
| View SEC Filings |
GMAB Valuation
| P/E Current | 20.888 |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | 32.93 |
| Price to Sales Ratio | 8.78 |
| Price to Book Ratio | 4.441 |
| Price to Cash Flow Ratio | 19.599 |
| Enterprise Value to EBITDA | 20.661 |
| Enterprise Value to Sales | 7.084 |
| Total Debt to Enterprise Value | 0.007 |
GMAB Efficiency
| Revenue/Employee | 1,084,538.346 |
| Income Per Employee | 286,506.67 |
| Receivables Turnover | 3.261 |
| Total Asset Turnover | 0.499 |
GMAB Liquidity
| Current Ratio | 13.341 |
| Quick Ratio | 13.318 |
| Cash Ratio | 11.326 |
GMAB Profitability
| Gross Margin | 96.643 |
| Operating Margin | 32.299 |
| Pretax Margin | 34.218 |
| Net Margin | 26.417 |
| Return on Assets | 13.19 |
| Return on Equity | 14.647 |
| Return on Total Capital | 13.16 |
| Return on Invested Capital | 14.354 |
GMAB Capital Structure
| Total Debt to Total Equity | 2.436 |
| Total Debt to Total Capital | 2.378 |
| Total Debt to Total Assets | 2.182 |
| Long-Term Debt to Equity | 2.151 |
| Long-Term Debt to Total Capital | 2.10 |